We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+19.62%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3B
AUM Growth
-$457M
(-13%)
Cap. Flow
-$196M
Cap. Flow
% of AUM
-6.55%
Top 10 Holdings %
Top 10 Hldgs %
45.74%
Holding
112
New
17
Increased
23
Reduced
25
Closed
15
Avg Time Held Equity + Options
8.8
quarters
Top 10 Avg Time Held Equity + Options
5.7
quarters
Top 20 Avg Time Held Equity + Options
5.8
quarters
Avg Time Held Equity only
9.8
quarters
Top 10 Avg Time Held Equity only
5.7
quarters
Top 20 Avg Time Held Equity only
5.8
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apogee Therapeutics
APGE
|
+$40.3M |
| 2 |
argenx
ARGX
|
+$39.9M |
| 3 |
Revolution Medicines
RVMD
|
+$39.2M |
| 4 |
Immunovant
IMVT
|
+$29.2M |
| 5 |
RayzeBio, Inc. Common Stock
RYZB
|
+$16.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$68.3M |
| 2 |
Vir Biotechnology
VIR
|
+$48M |
| 3 |
Amylyx Pharmaceuticals
AMLX
|
+$46.2M |
| 4 |
Apellis Pharmaceuticals
APLS
|
+$35.7M |
| 5 |
Madrigal Pharmaceuticals
MDGL
|
+$33.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.21% |
| 2 | Miscellaneous | 0.79% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
26
Revolution Medicines
RVMD
$40.4B
| $36.6M | 1.22% |
+1,321,795
| New | +$39.2M |
2023 Q3
0 quarters
|
|
27
DELISTED
SpringWorks Therapeutics
SWTX
| $35.2M | 1.17% |
1,520,416
-17,015
| -1% | -$465K |
2019 Q3
16 quarters
|
|
28
Axsome Therapeutics
AXSM
$8.19B
| $33.7M | 1.12% |
481,649
+210,156
| +77% | +$15.7M |
2023 Q2
1 quarter
|
|
29
Harmony Biosciences
HRMY
$2.16B
| $32.6M | 1.09% |
996,306
+104,936
| +12% | +$3.64M |
2022 Q2
5 quarters
|
|
30
DELISTED
RAPT Therapeutics
RAPT
| $31.9M | 1.06% |
240,082
-45,980
| -16% | -$7.51M |
2020 Q4
11 quarters
|
|
31
Rocket Pharmaceuticals
RCKT
$252M
| $31.1M | 1.04% |
1,517,467
+349,104
| +30% | +$6.35M |
2018 Q4
19 quarters
|
|
32
Nautilus Biotechnolgy
NAUT
$261M
| $28.8M | 0.96% |
9,111,151
| – | – |
2021 Q2
9 quarters
|
|
33
Acrivon Therapeutics
ACRV
$75M
| $28.8M | 0.96% |
3,007,858
| – | – |
2022 Q4
3 quarters
|
|
34
Tango Therapeutics
TNGX
$3.75B
| $27.2M | 0.91% |
+2,418,968
| New | +$14.8M |
2023 Q3
0 quarters
|
|
35
ADMA Biologics
ADMA
$2.31B
| $25M | 0.83% |
6,984,319
-4,915,936
| -41% | -$18.9M |
2016 Q3
28 quarters
|
|
36
Treace Medical Concepts
TMCI
$267M
| $24M | 0.8% |
1,834,060
-383,190
| -17% | -$7.01M |
2021 Q2
9 quarters
|
|
37
Tarsus Pharmaceuticals
TARS
$3.31B
| $23M | 0.77% |
1,296,416
| – | – |
2020 Q4
11 quarters
|
|
38
Cogent Biosciences
COGT
$4.87B
| $22.5M | 0.75% |
2,309,470
-350,000
| -13% | -$4.15M |
2020 Q3
12 quarters
|
|
39
Sarepta Therapeutics
SRPT
$1.74B
| $22.1M | 0.74% |
182,720
+101,646
| +125% | +$11.5M |
2022 Q3
4 quarters
|
|
40
Mirum Pharmaceuticals
MIRM
$5.17B
| $21.2M | 0.71% |
672,042
+70,476
| +12% | +$1.93M |
2023 Q1
2 quarters
|
|
41
Orchestra BioMed
OBIO
$344M
| $21.2M | 0.71% |
2,432,089
+379,221
| +18% | +$2.55M |
2023 Q1
2 quarters
|
|
42
Xenon Pharmaceuticals
XENE
$3.33B
| $21.1M | 0.7% |
617,500
-605,877
| -50% | -$22.7M |
2021 Q1
10 quarters
|
|
43
Verrica Pharmaceuticals
VRCA
$61.5M
| $19.6M | 0.65% |
503,898
| – | – |
2018 Q2
21 quarters
|
|
44
Biohaven
BHVN
$1.72B
| $19.6M | 0.65% |
751,820
+431,000
| +134% | +$8.96M |
2023 Q2
1 quarter
|
|
|
45
Madrigal Pharmaceuticals
MDGL
$10.4B
| $18.2M | 0.61% |
124,637
-178,350
| -59% | -$33.6M |
2021 Q4
7 quarters
|
|
46
Neurocrine Biosciences
NBIX
$13.7B
| $17.9M | 0.6% |
159,242
+59,192
| +59% | +$6.23M |
2013 Q2
41 quarters
|
|
47
Protagonist Therapeutics
PTGX
$8.96B
| $17.6M | 0.59% |
1,054,273
-415,488
| -28% | -$8.06M |
2023 Q1
2 quarters
|
|
|
48
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $17.2M | 0.58% |
+776,805
| New | +$16.3M |
2023 Q3
0 quarters
|
|
49
Cabaletta Bio
CABA
$287M
| $17.2M | 0.58% |
1,132,491
-412,509
| -27% | -$5.64M |
2022 Q4
3 quarters
|
|
50
Relay Therapeutics
RLAY
$3.8B
| $16.3M | 0.55% |
1,943,097
| – | – |
2020 Q3
12 quarters
|
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q3 2023 Portfolio in Review
As of Q3 2023, Perceptive Advisors held 112 positions worth $3B, down 13% from $3.45B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Perceptive Advisors withdrew a net $196M in Q3 2023, closing 15 positions and reducing 25 holdings. Its most notable exit was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $68.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Perceptive Advisors opened a new position in Apogee Therapeutics worth $38.9M.
- Perceptive Advisors's largest Q3 2023 buy was Apogee Therapeutics: 1,827,901 shares worth $38.9M.
- Perceptive Advisors added most to argenx in Q3 2023, an estimated $39.9M increase.
- Perceptive Advisors's biggest Q3 2023 reduction was Amylyx Pharmaceuticals, cutting an estimated $46.2M.
- Perceptive Advisors fully exited Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2023, selling an estimated $68.3M.
- Perceptive Advisors's ten largest holdings make up 46% of its $3B portfolio in Q3 2023.
- Perceptive Advisors opened 17 new positions and closed 15 in Q3 2023.
- Perceptive Advisors's portfolio value fell 13% quarter-over-quarter to $3B.
Based on Perceptive Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.